MDx Health Signs Exclusive Canadian Agreement
MDx Health has signed an exclusive distribution deal to make its liquid biopsy prostate cancer test available in Canada.
You may also be interested in...
MDx Health has named a new CEO to lead its commercial growth following a disappointing set of results in 2018.
Cancer diagnostics company MDxHealth is poised for more commercial growth in 2018 following a move to larger lab facilities in Nijmegen, the Netherlands. The move is part of the company's strategy to grow commercialization of its SelectMDx prostate cancer test in Europe and conduct additional R&D activities.
Barcode Diagnostics is developing a nanotechnology for personalized cancer drug screening. The start-up’s aim is to provide physicians with a tool that matches patients with the most effective medicine, during the different stages of disease.